The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- 
      
  
Fall 2021 RFP: Outcome Measures, 2021Characterization of Sterols in CSF and Plasma as a Possible Biomarker for Parkinson’s DiseaseStudy Rationale: Sterols, including cholesterol, are very abundant in the brain, where they form important components of cell membranes and act as signaling molecules within and between cells... 
- 
      
  
Target Advancement Program, 2021Enhancing Treatment Efficacy by Eliminating L-dopa Metabolizing Gut BacteriaStudy Rationale: Levodopa (L-dopa) is the primary medication used to treat Parkinson’s disease (PD). For L-dopa to exert its effect, it must enter the brain and be converted to the chemical dopamine... 
- 
      
  
Research Grant, 2021Changing Rhythms in Parkinson’s Disease: Development of Motor and Non-motor Markers of Progression Based on Continuous Daily MonitoringStudy Rationale: Although new treatments are being developed to slow the progression of Parkinson’s disease (PD), assessing their effectiveness remains a challenge. Standard evaluations, conducted in... 
- 
      
  
Research Grant, 2021Gut Inflammation and Microbial Imbalance in Parkinson’s DiseaseStudy Rationale: Studies show that the intestinal environment can affect the activity of the nervous system, and inflammation in the gut could contribute to the brain changes associated with Parkinson... 
- 
      
  
Outcome Measures, 2021Development of a Method for Assessing the Effectiveness of Alpha-synuclein ImmunotherapyStudy Rationale: Parkinson’s disease (PD) is characterized by the buildup of misfolded forms of alpha-synuclein. A vaccine designed to target this abnormal protein has demonstrated safety... 
- 
      
  
Therapeutic Pipeline Program, 2021Development of an Anti-inflammatory Drug for the Treatment of Parkinson’s DiseaseStudy Rationale: Persistent activation of the immune cells that reside in the brain leads to a state of chronic inflammation that contributes to the degeneration of neurons in Parkinson’s disease (PD)... 
 
  Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.